170 related articles for article (PubMed ID: 35354251)
1. Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes.
Anastasopoulou S; Nielsen RL; Als-Nielsen B; Banerjee J; Eriksson MA; Helenius M; Heyman MM; Johannsdottir IM; Jonsson OG; MacGregor S; Mateos MK; Mayoh C; Mikkel S; Myrberg IH; Niinimäki R; Schmiegelow K; Taskinen M; Vaitkeviciene G; Warnqvist A; Wolthers B; Harila-Saari A; Ranta S
Haematologica; 2022 Oct; 107(10):2318-2328. PubMed ID: 35354251
[TBL] [Abstract][Full Text] [Related]
2. Seizures during treatment of childhood acute lymphoblastic leukemia: A population-based cohort study.
Anastasopoulou S; Heyman M; Eriksson MA; Niinimäki R; Taskinen M; Mikkel S; Vaitkeviciene GE; Johannsdottir IM; Myrberg IH; Jonsson OG; Als-Nielsen B; Schmiegelow K; Banerjee J; Ranta S; Harila-Saari A
Eur J Paediatr Neurol; 2020 Jul; 27():72-77. PubMed ID: 32340855
[TBL] [Abstract][Full Text] [Related]
3. Does minimal central nervous system involvement in childhood acute lymphoblastic leukemia increase the risk for central nervous system toxicity?
Anastasopoulou S; Harila-Saari A; Als-Nielsen B; Eriksson MA; Heyman M; Johannsdottir IM; Marquart HV; Niinimäki R; Pronk CJ; Schmiegelow K; Vaitkeviciene G; Thastrup M; Ranta S
Pediatr Blood Cancer; 2022 Jul; 69(7):e29745. PubMed ID: 35488712
[TBL] [Abstract][Full Text] [Related]
4. Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Clinical characteristics, risk factors, course, and outcome of disease.
Anastasopoulou S; Eriksson MA; Heyman M; Wang C; Niinimäki R; Mikkel S; Vaitkevičienė GE; Johannsdottir IM; Myrberg IH; Jonsson OG; Als-Nielsen B; Schmiegelow K; Banerjee J; Harila-Saari A; Ranta S
Pediatr Blood Cancer; 2019 May; 66(5):e27594. PubMed ID: 30592147
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia.
Banerjee J; Niinimäki R; Lähteenmäki P; Hed Myrberg I; Arola M; Riikonen P; Lönnqvist T; Palomäki M; Ranta S; Harila-Saari A; Taskinen M
Pediatr Blood Cancer; 2020 Feb; 67(2):e27999. PubMed ID: 31674724
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.
Mateos MK; Marshall GM; Barbaro PM; Quinn MCJ; George C; Mayoh C; Sutton R; Revesz T; Giles JE; Barbaric D; Alvaro F; Mechinaud F; Catchpoole D; Lawson JA; Chenevix-Trench G; MacGregor S; Kotecha RS; Dalla-Pozza L; Trahair TN
Haematologica; 2022 Mar; 107(3):635-643. PubMed ID: 33567813
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group.
Duffner PK; Armstrong FD; Chen L; Helton KJ; Brecher ML; Bell B; Chauvenet AR
J Pediatr Hematol Oncol; 2014 Jan; 36(1):8-15. PubMed ID: 24345882
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.
Parasole R; Petruzziello F; Menna G; Mangione A; Cianciulli E; Buffardi S; Marchese L; Nastro A; Misuraca A; Poggi V
Leuk Lymphoma; 2010 Jun; 51(6):1063-71. PubMed ID: 20470218
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia].
Liu J; Lu AD; Zuo YX; Wu J; Huang ZZ; Jia YP; Ding MM; Zhang LP; Qin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):948-953. PubMed ID: 36241238
[TBL] [Abstract][Full Text] [Related]
10. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
11. [Complications in the central nervous system during chemotherapy for childhood acute lymphoblastic leukemia: JACLS ALL-02 study].
Umeda K; Yoshida M; Suzuki N; Endo M; Sato A; Hori H; Isogai M; Matsumoto K; Hara JI; Hasegawa D; Hashii Y; Chayama K; Miyaji R; Nishimura S; Tanizawa A; Uami I; Horibe K; Wakazono Y; Yagi K
Rinsho Ketsueki; 2007 Mar; 48(3):204-11. PubMed ID: 17441477
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia.
Nassar SL; Conklin HM; Zhou Y; Ashford JM; Reddick WE; Glass JO; Laningham FH; Jeha S; Cheng C; Pui CH
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28130818
[TBL] [Abstract][Full Text] [Related]
14. Posterior Reversible Encephalopathy Syndrome: Risk Factors and Impact on the Outcome in Children With Acute Lymphoblastic Leukemia Treated With Nordic Protocols.
Banerjee JS; Heyman M; Palomäki M; Lähteenmäki P; Arola M; Riikonen PV; Möttönen MI; Lönnqvist T; Taskinen MH; Harila-Saari AH
J Pediatr Hematol Oncol; 2018 Jan; 40(1):e13-e18. PubMed ID: 29200159
[TBL] [Abstract][Full Text] [Related]
15. Patterns and Outcomes of Acute Central Nervous System Complications During Treatment of Childhood Acute Lymphoblastic Leukemia: A Single-center Experience.
Hamoda A; Bedair M; Semary SF; Youssef A; Hafez H
J Pediatr Hematol Oncol; 2024 Mar; 46(2):72-79. PubMed ID: 38132573
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients.
Schroyen G; Meylaers M; Deprez S; Blommaert J; Smeets A; Jacobs S; Sunaert S; Sleurs C; Uyttebroeck A
J Chemother; 2020 Nov; 32(7):327-343. PubMed ID: 32799637
[TBL] [Abstract][Full Text] [Related]
17. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Millan NC; Pastrana A; Guitter MR; Zubizarreta PA; Monges MS; Felice MS
Leuk Res; 2018 Feb; 65():86-93. PubMed ID: 29328996
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
Rank CU; Toft N; Tuckuviene R; Grell K; Nielsen OJ; Frandsen TL; Marquart HVH; Albertsen BK; Tedgård U; Hallböök H; Ruud E; Jarvis KB; Quist-Paulsen P; Huttunen P; Wartiovaara-Kautto U; Jónsson ÓG; Trakymiene SS; Griškevičius L; Saks K; Punab M; Schmiegelow K
Blood; 2018 May; 131(22):2475-2484. PubMed ID: 29661787
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of central nervous system relapse of pediatric acute lymphoblastic leukemia: Impact of routine cytological CSF analysis at the time of intrathecal chemotherapy.
Gassas A; Krueger J; Alvi S; Sung L; Hitzler J; Lieberman L
Pediatr Blood Cancer; 2014 Dec; 61(12):2215-7. PubMed ID: 25212396
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Asberg A; Helt LR; Frandsen T; Schmiegelow K
Eur J Haematol; 2016 Feb; 96(2):160-9. PubMed ID: 25867866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
